Jaguar Health Provides Updates Regarding Commercial, Educational & Product Development Programs and 2017 Results for Mytesi Since Merger (August–December 2017) - Seite 2

Sales is a measure that is recognized under accounting principles generally accepted in the United States of America (“GAAP”), in accordance with new 2018 revenue recognition rules, still under review by the Company and its auditors. As a result, the preliminary Mytesi^® sales figures provided herein are subject to revision until the Company reports final fourth quarter fiscal 2017 results no later than March 30, 2018.

Commercialized directly by Napo in the U.S., Mytesi^® is the only antidiarrheal studied in and U.S. FDA-approved for the symptomatic relief of noninfectious diarrhea in adults living with HIV/AIDS on antiretroviral therapy (ART). Mytesi^® is a prescription treatment for diarrhea that works differently, by acting locally in the GI tract to normalize the flow of water. Mytesi^® does not have drug-drug interactions with ART and does not affect GI motility.

Napo Launches Health Care Practitioner and Patient Advocate Speaker Bureau – Plans to Conduct More Than 1,400 Educational Events in 2018

Napo recently completed the training of 29 health care practitioners (HCPs) and ten patient advocates to serve as members of the Napo Speakers Bureau. Medical education presentations led by participating HCPs—a group that includes HIV/AIDS specialists, infectious disease specialists, gastroenterologists, colorectal surgeons, and nurse practitioners—will focus on the prevalence and pathophysiology of gastrointestinal consequences of HIV infection and on the latest treatment options for HIV-related diarrhea. Presentations given by patient advocate members will provide information to people living with HIV (PLWH) about the prevalence of diarrhea in PLWH and offer guidance about talking to HCPs regarding diarrhea-related concerns.

As part of Napo’s medical and patient education program, the Mytesi^® direct sales force are planning more than 1,400 live and virtual educational events for 2018. Live events will largely take place in the following key geographies covered by the Mytesi^® sales team: Miami/South Florida, Los Angeles/Palm Springs, New York, Houston, Chicago/St. Louis, Indianapolis, Kansas City, Alabama, Atlanta, San Francisco, DC, Pennsylvania, New Jersey, Delaware, Maryland, Mississippi and Louisiana.

“Since the merger of Jaguar and Napo, we have both initiated and dramatically expanded Mytesi^®-related commercial, educational and development initiatives, including the creation of our direct sales force and our scientific advisory board, the roll-out of direct-to-consumer advertising campaigns, publication-focused efforts, government affairs activities regarding neglected comorbidities of HIV, and the launch of the Napo Speaker Bureau,” Conte commented. “Mytesi^® sales and the awareness of a novel first-in-class approach to managing diarrhea tested specifically in the HIV population are clearly benefiting from the programs we’ve put in place—in addition to the efforts of our recently expanded team of experienced HIV sales representatives.”